The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

British Journal of Cancer
M H BronchudT M Dexter

Abstract

Granulocyte colony stimulating factor (G-CSF) was given to 17 patients with advanced breast and ovarian cancer in order to increase the intensity and effectiveness of chemotherapy. Treatment with doxorubicin, at doses of 75 mg m-2 (n = 4 patients), 100 mg m-2 (n = 5), 125 mg m-2 (n = 6) and 150 mg m-2 (n = 2), was followed by infusion of G-CSF for 11 days. G-CSF administration resulted in a return of the absolute neutrophil count to normal or above normal levels within 12-14 days at all dose levels of doxorubicin used and allowed the administration of up to three cycles of high dose chemotherapy at 14 day intervals. An absolute neutrophil count greater than 2.5 x 10(9)l-1 was not reached until day 19-21 after 75 mg m-2 of doxorubicin given without G-CSF. At doses of doxorubicin of 125 mg m-2 and 150 mg m-2 all tumours regressed rapidly, although there was marked epithelial toxicity. The overall response rate in patients with advanced breast cancer was 80% with a median time to progression of 6 months. Two months after doxorubicin-G-CSF therapy there was a pronounced improvement of symptoms compared with before treatment. Thus the effectiveness of chemotherapy may be enhanced and treatment duration shortened by the use of G-CSF ...Continue Reading

Citations

Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·C WalshJ L Speyer
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·M H BronchudP M Wilkinson
Nov 30, 1993·Annals of the New York Academy of Sciences·J CrownT Gilewski
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·F Takaku
Sep 1, 1994·Human Gene Therapy·C HesdorfferM Begg
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·T TajimaM Kubota
Aug 6, 2016·Angewandte Chemie·Kegan S SunderlandChuanbin Mao
Jul 1, 1990·British Journal of Haematology·G Morstyn
Jan 1, 1991·Growth Factors·A MigdalskaT M Dexter
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·A du BoisT Bauknecht
Jan 1, 1995·Cancer Investigation·L VahdatJ Crown
Aug 5, 1994·Pharmacy World & Science : PWS·M C MonteroM Atienza
Oct 1, 1995·Cancer Control : Journal of the Moffitt Cancer Center·R Quilitz
Jan 1, 1991·Cancer Investigation·W P Sheridan
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C HudisL Norton
Mar 1, 1992·Breast Cancer Research and Treatment·E L Korn, R Simon
Sep 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paola PapaldoFederico Calabresi
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xianglin L DuShenying Fang
Jul 1, 1992·Infection·F Herrmann
Jan 1, 1994·European Journal of Haematology. Supplementum·J HarmenbergE Hellström-Lindberg
Apr 1, 1995·British Journal of Haematology·J TomeczkowskiK W Sykora
May 1, 1994·The Australian & New Zealand Journal of Obstetrics & Gynaecology·F HicksD Dodwell
Feb 1, 1996·Cancer Biotherapy & Radiopharmaceuticals·A Jakubowski, J Gabrilove
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·J Carmo-PereiraR D Rubens
Nov 23, 2012·Journal of Translational Medicine·J Christopher MizerAmit N Patel
Jul 9, 1992·The New England Journal of Medicine·G J Lieschke, A W Burgess

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.